Combination treatment in CTCL: The current role of bexarotene

Giornale Italiano di Dermatologia e Venereologia

Volumn 147, Issue 6, 2012, Pages 573-579

  Delfino, C ^a   Grandi, V ^a   Pileri, A ^b   Rupoli, S ^c   Quaglino, P ^d   Alterini, R ^a   Goteri, G ^c   Canafoglia, L ^c   Pimpinelli, N ^a  

^a UNIVERSITY OF FLORENCE   (Italy)

^b UNIVERSITY OF BOLOGNA   (Italy)

^c UNIVERSITÀ POLITECNICA DELLE MARCHE   (Italy)

^d UNIVERSITY OF TURIN   (Italy)

Author keywords

Lymphoma, T cell, cutaneous; Photochemotherapy; Skin diseases

Indexed keywords

ALPHA INTERFERON; BEXAROTENE; DOXORUBICIN; GEMCITABINE; LIPOSOME;

CANCER CHEMOTHERAPY; CANCER STAGING; CUTANEOUS T CELL LYMPHOMA; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; HUMAN; LONG TERM CARE; LOW DRUG DOSE; MAINTENANCE THERAPY; MONOTHERAPY; PATIENT CARE; PUVA; REVIEW; TREATMENT RESPONSE;

EID: 84874375048     PISSN: 03920488     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (54)

1. Willemze R, Jaffe ES, Burg G, Cerroni L, Berti E, Swerdlow SH et al. WHO-EORTC classification for cutaneous lymphomas. Blood 2005;17:3768-85.
2. Swerdlow SH, Campo E, Harrys NL, Jaffe ES, Pileri SA, Stein H et al. WHO Classification of Tumors of Haematopoietic and Lymphoid Tissues. Lyon: IARC; 2008.
3. Olsen E, Vonderheid E, Pimpinelli N, Willemze R, Kim Y, Knobler R et al. Revisions to the staging and classification of mycosis fungoides and Sézary syndrome: a proposal of the International Society for Cutaneous Lymphomas (ISCL) and the cutaneous lymphoma task force of the European Organization of Research and Treatment of Cancer (EORTC). Blood 2007;110:1713-22.
4. Trautinger F, Knobler R, Willemze R, Peris K, Standler R, Laroche L et al. EORTC consensus recommendations for the treatment of mycosis fungoides/Sézary Syndrome. European Journal of Cancer 2006;42:1014-30.
5. Olsen EA, Rook AH, Zic J, Kim Y, Porcu P, Querfeld C et al. Sézary syndrome: immunopathogenesis, literature review of therapeutic options, and reccomendtions for therapy by the United States Cutaneous Lymphoma Consortium (USCLC). J Am Acad Dermatol 2011;64:352-404.
6. Wong HK, Mishra A, Hake T, Porcu P. Evolving insights in the pathogenesis and therapy of cutaneous T-cell lymphoma (Mycosis Fungoides and Sezary Syndrome). Br J Haematol, 2011;155:150-66.
7. Lasingan F, Foss F. Current and emerging treatment strategies for cutaneous T-cell lymphoma. Drugs 2010;70:273-86.
8. Dummer R, Assaf C, Bagot M, Gniadecki R, Hauschild A, Knobler R et al. Maintenance therapy in cutaneous T-cell lymphoma: who, when, what? Eur J Cancer 2007;43:2321-9.
9. Belloni B, Johansen N, Glass LF, Dummer R. Recent advances in the management of cutaneous lymphomas. Semin Oncol 2012;39:150-62.
10. Bloom T, Kuzel TM, Querfeld C, Guitart J, Rosen ST. Cutaneous T-cell lymphomas: a review of new discoveries and treatments. Curr Treat Options Oncol 2012;13:102-21.
11. Zhang C, Duvic M. Treatment of cutaneous T-cell lymphomas with retinoids. Dermatol Ther 2006;19:264-71.
12. Gniadecki R, Assaf C, Bagot M, Dummer R, Duvic M, Knobler R et al. The optimal use of bexarotene in cutaneous T-cell lymphoma. Br J of Dermatol 2007;157:433-40.
13. Zhang C, Hazarika P, Ni X, Weidner DA, Duvic M. Induction of apoptosis by bexarotene in cutaneous T-cell lymphoma cells: relevance to mechanism of therapeutic action. Clin Cancer Res 2002;8:1234-40.
14. Richardson SK, Newton SB, Bach TL, Budgin JB, Benoit BM, Lin JH et al. Bexarotene blunts malignant T-cell chemotaxis in Sezary syndrome: reduction of chemokine receptor a-positive lymphocytes and decreased chemotaxis to thymus and activation-regulated chemokine. Am J of Hematol 2007;82:792-7.
15. Qu L, Tang X. Bexarotene: a promising anticancer agent. Cancer Chemother Pharmacol 2010;65:201-5.
16. Duvic M, Martin AG, Kim Y, Olsen E, Wood GS, Crowley CA et al. Phase 2 and 3 clinical trial of oral bexarotene (Targretin capsules) for the treatment of refractory of persistent early-stage cutaneous T-cell lymphoma. Arch Dermatol 2001;137:581-93.
17. Duvic M, Hymes K, Heald P, Breneman D, Martin AG, Myskowski P et al. Bexarotene is effective and safe for treatment of refractory advanced-stage cutaneous T-cell lymphoma: multinational phase II-III trial results. J Clin Oncol 2001;19:2456-71.
18. Assaf C, Bagot M, Dummer R, Duvic M, Gniadecki R, Knobler R et al. Minimizing adverse side-effects of oral bexarotene in cutaneous T-cell lymphoma: an expert opinion. Br J Dermatol 2006;155:261-6.
19. Scarisbrick JJ, Morris S, Azurdia R, Illidge T, Parry E, Graham-Brown R et al. UK Consensus statement on safe clinical prescribing of bexarotene for patients with cutaneous T-cell lymphoma. Br J of Dermatol 2012 [Epub ahead of print].
20. McGinnis K, Junkins-Hopkins JM, Crawford G, Shapiro M, Rook AH, Vittorio CC. Low-dose oral bexarotene in combination with low-dose interferon alfa in the treatment of cutaneous T-cell lymphoma: clinical synergism and possible immunologic mechanisms. J Am Acad Dermatol 2004;50:375-9.
21. Straus DJ, Duvuc M, Kuzel T, Horwitz S, Demierre MF, Myskowsky P et al. Results of a phase II trial of oral bexarotene (Targretin) combined with interferon alfa-2b (Intron-A) for patients with cutaneous T-cell lymphoma. Cancer 2007;109:1799-803.
22. Tooker P, Yen W-C, Ng S-C, Negro-Vilar A, Hermann TW. Bexarotene (LGD1069, Targretin), a selective retinoid X receptor agonist, prevents and reverses gemcitabine resistance in NSCLC cells by modulating gene amplification. Cancer Res 2007;67:4425-33.
23. Hermann TW, Yen WC, Tooker P, Fan B, Roegner K, Negro-Vilar A et al. The retinoid X receptor agonist bexarotene (Targretin) synergistically enhances the growth inhibitory activity of cytotoxic drugs in non-small cell lung cancer cells. Kung Cancer 2005;50:9-18.
24. Yen WC, Corpuz MR, Prudente RY, Cooke TA, Bissonnette RP, Negro-Vilar A et al. A selective retinoid X receptor agonist bexarotene (Targretin) prevents and overcomes acquired paclitaxel (Taxol) resistance in human non-small cell lung cancer. Clin Cancer Res 2004;10:8656-64.
25. Yen WC, Lamph WW. The selective retinoid X receptor agonist bexarotene (LGD1069, Targretin) prevents and overcomes multidrug resistance in advanced breast carcinoma. Mol Cancer Ther 2005;4:824-34.
26. Yen WC, Lamph WW. The selective retinoid X receptor agonist bexarotene (LGD1069, Targretin) prevents and overcomes multidrug resistance in advanced prostate cancer. Prostate 2006;66:305-16.
27. Yen WC, Prudente RY, Lamph WW. Synergistic effect of a retinoid X receptor-selective ligand bexarotene (LGD1069, Targretin) and paclitaxel (Taxol) in mammary carcinoma. Breast Cancer Res Treat 2004;88:141-8.
28. Singh F, Lebwohl MG. Cutaneous T-cell lymphoma treatment using bexarotene and PUVA: a case series. J Am Acad Dermatol 2004;51:570-3.
29. Talpur R, Ward S, Apisarnthanarax N, Breuer-McHam J, Duvic M. Optimizing bexarotene therapy for cutaneous T-cell lymphoma. J Am Acad Dermatol 2002;47:672-84.
30. Dummer R. Emerging drugs in cutaneous T-cell lymphomas. Expert Opin Emerg Drugs 2005;10:381-92.
31. Guitart J. Combination treatment modalities in cutaneous T-cell lymphoma (CTCL). Semin Oncol 2006;33(Suppl 3):S17-S20.
32. Pothiawala SZ, Baldwin BT, Cherpelis BS, Lien MH, Fenske NA. The role of phototherapy in cutaneous T-cell lymphoma. J Drugs Dermatol 2010;9:764-72.
33. Lokitz ML, Wong HK. Bexarotene and narrowband ultraviolet B phototherapy combination treatment for mycosis fungoides. Photodermatol Photoimmunol Photomed 2007;23:255-7.
34. Skiantaris MP, Tsirigotis P, Stavroyianni N, Argyropoulos K, Girkas K, Chondropoulos S et al. Management of cutaneous T-Cell lymphoma patients with extracorporeal photopheresis. The Hellenic experience. Transfus Apher Sci 2012;46:189-93.
35. Atta M, Papanicolaou N, Tsirigotis P. The role of extracorporeal photopheresis in the treatment of cutaneous T-cell lymphomas. Transfus Apher Sci 2012;195-202.
36. Mestel DS, Assaf C, Steinhoff M, Beyer M, Moebs M. Emerging drugs in cutaneous T cell lymphomas. Expert Opin. Emerging drugs 2008;13:345-61.
37. Vose J, Armitage J, Weisenburger D. Internationalperipheral T-cell and natural killer/T-cell lymphoma study: pathology findings and clinical outcomes. J Clin Oncol 2008;26:4124-30.
38. Phillips AA, Owens C, Lee S, Bhagat G. An update on the management of peripheral T-cell lymphoma and emerging treatment options. J Blood Med 2011;2:119-29.
39. Kannangara AP, Levitan D, Fleischer AB Jr. Evaluation of the efficacy of the combination of oral bexarotene and methotrexate for the treatment of early stage treatment-refractory cutaneous T-cell lymphoma. Journal of Dermatol Treatment 2009;20:3;169-76.
40. McGinnis KS, Shapiro M, Vittorio CC, Rook AH, Junkins-Hopkins JM. Psoralen plus long-wave UV-A (PUVA) and bexarotene therapy: an effective and synergistic combined adjunct to therapy for patients with advanced cutaneous T-cell lymphoma. Arch Dermatol 2003;139:771-5.
41. Coors EA, von den Driesch P. Treatment of mycosis fungoides with bexarotene and psoralen plus ultraviolet A. Br J Dermatol 2005;152:1379-81.
42. Ortiz-Romero PL, Sanchez-Largo ME, Sanz H, Garcia-Romero D, Rosales B, Valverde R et al. Treatment of mycosis fungoides with PUVA and bexarotene. Actas Dermosifiliogr 2006;97:311-8.
43. Papadavid E, Antoniou C, Nikolaou V, Siakantaris M, Vassilakopoulos TP, Striatogos A et al. Safety and efficacy of low-dose bexarotene and PUVA in the treatment of patients with mycosis fungoides. Am J Clin Dermatol 2008;9:169-73.
44. Whittaker S, Ortiz P, Dummer R, Ranki A, Hasan B, Meulemans B et al. Efficacy and safety of bexarotene combined with psoralenultraviolet A (PUVA) compared with PUVA treatment alone in stage IB-IIA mycosis fungoides: final results from the EORTC Cutaneous Lymphoma Task Force phase III randomized clinical trial 21011 (NCT00056056). Br J Dermatol 2012;167:678-87.
45. Thomsen K, Hammar H, Molin L, Volden G. Retinoid plus PUVA (RePUVA) and PUVA in mycosis fungoides, plaque stage. A report from the Scandinavian Mycosis Fungoides Group. Acta Derm Venereol 1989;69:536-8.
46. Zachariae H, Thestrup-Pedersen K. Interferon alpha and etretinate combination treatment of cutaneous T-cll lymphoma. J Invest Dermatol 1990;95(6 Suppl):206S-8S.
47. Knobler RM, Trautinger F, Radaszkiewicz T, Kokoschka EM, Micksche M. Treatment of cutaneous T cell lymphoma with a combination of low-dose interferon alfa-2b and retinoids. J Am Acad Dermatol 1991;24(2 Pt 1):247-52.
48. Dreno B, Claudy A, Meynadier J, Verret JL, Souteyrand P, Ortonne JP et al. The treatment of 45 patients with cutaneous T-cell lymphoma with low doses of interferon-alpha 2a and etretinate. Br J Dermatol 1991;125:456-9.
49. Abbott RA, Whittaker SJ, Morris SL, Russell-Jones R, Hung T, Bashir SJ et al. Bexarotene therapy for mycosis fungoides and Sézary syndrome. Br J Dermatol 2009;160:1299-307.
50. Marchi E, Alinari L, Tani M, Stefoni V, Pimpinelli N, Berti E et al. Gemcitabine as frontline treatment for cutaneous T-cell lymphoma: phase II study of 32 patients. Cancer 2005;104:2437-41.
51. Wollina U, Dummer R, Brockmeyer NH, Konrad H, Busch JO, Kaatz M et al. Multicenter study of pegylated liposomal doxorubicin in patients with cutaneous T-cell lymphoma. Cancer 2003;98:993-1001.
52. Pulini S, Rupoli S, Goteri G, Pimpinelli N, Alterini R, Tassetti A et al. Pegylated liposomal doxorubicin in the treatment of primary cutaneous T-cell lymphoma. Haematologica 2007;92:686-9.
53. Duvic M. Systemic monotherapy vs combination therapy for CTCL: rationale and future strategies. Oncology (Williston Park) 2007;21(2 Suppl 1):33-40.
54. Vakeva L, Ranki A, Hahtola S. Ten-year experience of bexarotene therapy for cutaneous T-cell lymphoma in Finland. Acta Derm Venereol 2012;92:258-63.